GLP-1 Drugs and Addiction: A New Frontier in Substance Use Treatment

Last Updated: March 2026

The medication class known as GLP-1 receptor agonists, already transforming obesity and type 2 diabetes treatment, is now showing remarkable promise in an unexpected arena: addiction. Recent research, notably a large observational study published in The BMJ in 2025, found that GLP-1 drug initiation was associated with a 51% lower risk of incident alcohol use disorder among US veterans with type 2 diabetes, compared to those initiating other diabetes medications [1]. This finding is part of a growing body of evidence suggesting these drugs could fundamentally alter how the brain responds to addictive substances.

The Unexpected Link: GLP-1s and Brain Reward Pathways

GLP-1 receptor agonists (like semaglutide and liraglutide) primarily work by mimicking the natural hormone GLP-1, slowing gastric emptying, increasing insulin release, and reducing appetite. However, GLP-1 receptors are also present in the brain, particularly in areas associated with reward, motivation, and decision-making—the very pathways implicated in addiction. This dual action is central to their potential impact on substance use disorders (SUDs).

Addiction is fundamentally a disorder of the brain’s reward system. Substances like alcohol, nicotine, and opioids hijack dopamine pathways, creating intense feelings of pleasure and motivation for repeated use. Researchers hypothesize that GLP-1 drugs may modulate these pathways, dampening the “reward signal” from addictive substances without causing overt sickness or aversion. Instead, they appear to make the substances simply less appealing.

Early Evidence: From Animal Models to Human Trials

The journey to understanding GLP-1s’ role in addiction began with compelling animal research.

Animal Studies: Quieting the “Drug Noise”

Seminal studies, often highlighted by publications like STAT News, have demonstrated significant effects in animal models. In one notable experiment, vervet monkeys, primates known for voluntarily consuming alcohol, were given semaglutide. They drank significantly less, not because they felt ill, but because alcohol seemed to lose its inherent appeal [3].

As reported by STAT News, the effect on these animals was distinct: “They drank significantly less, not because alcohol made them feel ill, but because it had lost its appeal” [3]. This suggests a more profound neurobiological shift rather than simple adverse reaction. Similar results have been observed across various animal species and substances, including cocaine, nicotine, and opioids, indicating a broad mechanism of action on the brain’s reward circuitry.

Observational Data: Real-World Trends in Veterans

The observational study in The BMJ provides robust real-world data [1]. Researchers analyzed electronic health records from the US Department of Veterans Affairs, comparing over 117,000 veterans with type 2 diabetes who initiated GLP-1 receptor agonists to an equal number who started other non-GLP-1 diabetes medications. The study tracked the incidence of various SUDs over several years.

The findings were consistent across multiple substances:

Source: The BMJ, 2025 [1]

These data suggest a substantial protective effect of GLP-1 drugs against developing SUDs. The hazard ratio of 0.49 for alcohol use disorder, for instance, means individuals on GLP-1s had approximately half the risk of being diagnosed with new onset alcohol use disorder compared to the control group. The study also examined protocol 2, which found a reduced risk of SUD-related adverse clinical outcomes (like emergency department visits or hospitalizations) among those with pre-existing SUDs who started GLP-1s.

Randomized Controlled Trials: Focusing on Alcohol Use Disorder

Beyond observational data, randomized controlled trials (RCTs) are directly testing the efficacy of GLP-1 drugs in treating established SUDs. One such trial, published in JAMA Psychiatry in 2025, focused on semaglutide for alcohol use disorder (AUD) [2].

In this randomized, placebo-controlled clinical trial, adults diagnosed with AUD received either once-weekly semaglutide or a placebo. The results were compelling: semaglutide not only reduced craving for alcohol but also significantly decreased weekly alcohol consumption. Participants in the semaglutide group reported fewer heavy drinking days and a greater reduction in overall alcohol intake compared to those on placebo.

This study directly supports the hypothesis that GLP-1 receptor agonists can be an effective intervention for AUD, marking a significant step towards their potential use in clinical addiction treatment. The dual impact on craving and consumption is particularly promising, addressing key challenges in managing AUD.

The Mechanism: Dopamine, Reward, and Hedonic Hunger

The emerging consensus among researchers is that GLP-1s influence the mesolimbic dopamine system, a crucial reward pathway in the brain. This system is responsible for processing pleasure, motivation, and reinforcement learning. Addictive substances intensely activate this pathway, leading to compulsive seeking and use.

GLP-1 receptor activation in the brain, particularly in areas like the ventral tegmental area and nucleus accumbens, appears to modulate dopamine release and signaling. This modulation could reduce the rewarding properties of addictive substances, thereby decreasing their appeal and the drive to consume them. It’s a similar mechanism to how GLP-1s reduce “hedonic hunger”—the desire for highly palatable, rewarding foods—which can also be seen as a form of addictive eating.

Future Implications and Research Directions

The implications of these findings are profound. If GLP-1 receptor agonists prove broadly effective and safe for treating SUDs, they could offer a novel pharmacological approach to a global health crisis. Current treatments for addiction often have limited efficacy, significant side effects, or are underutilized.

Further research is critical. This includes:

• Larger, longer-term RCTs: Needed to confirm efficacy, evaluate optimal dosing, and assess long-term safety in diverse populations with various SUDs.
• Mechanism of action studies: Delving deeper into the specific neural circuits and neurotransmitter systems affected by GLP-1s to refine treatment strategies.
• Combination therapies: Investigating whether GLP-1s can enhance the effectiveness of existing behavioral or pharmacological addiction treatments.
• Broader SUD application: Expanding research beyond AUD to other substance use disorders, including opioid, stimulant, and nicotine dependence.

The evidence points to GLP-1 receptor agonists as a transformative class of drugs. Their potential to address not just metabolic health but also the complex neurobiology of addiction positions them at the forefront of medical innovation.

Sources

1. Jie-Bin Kuo, Chang-Ching Yang, Fang-Jung Ou, Tsung-Hsien Lee, Che-Hung Lin, Pao-Hsien Chu, Sheng-Wei Lin, Min-Wei Huang, Chi-Shin Huang, Chung-Lieh Hung, Jien-Jiun Chen, Hsing-Fang Chen, Yu-Feng Chen, Yi-Ting Tsai, Ming-Hsun Lee, Chao-Yu Liu. Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. The BMJ. 2025;392:e086886. https://www.bmj.com/content/392/bmj-2025-086886
2. Völker KM, Prechtl BLH, Bormann NL, Choi DS. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025 Apr 1;82(4):395-405. doi:10.1001/jamapsychiatry.2024.4789. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2816301
3. Cross, Emily. GLP-1 drugs appear to silence ‘drug noise’ in new study. STAT News. March 4, 2026. https://www.statnews.com/2026/03/04/glp-1-drugs-addiction-biological-driver/